Back to Atomoxetine (Strattera)

Daily-use question

Can I take Atomoxetine (Strattera) every day?

Daily use is reasonable for most users — cycle if effect attenuates. Atomoxetine (Strattera) can be used daily by most healthy adults at standard doses. Watch for tolerance signs — diminishing subjective effect at the same dose — and either cycle off (1 week per quarter) or rotate compounds within the same goal.

Class

stimulant

Safety score

4 / 5

Frequency

1-2 doses

Half-life

5h

Key facts

typical dose
40–100 mg
dose frequency
1-2 doses
timing
AM
with food
optional
onset
60 minutes
half-life
5 hours
safety score
4/5
evidence grade
A
class
stimulant
PubMed citations
3800
legal status (US)
Prescription-only
legal status (UK)
Prescription-only
legal status (EU)
Prescription-only
legal status (AU)
Prescription-only
primary mechanism
Selective norepinephrine reuptake inhibitor (NRI) — blocks the norepinephrine transporter, increasing extracellular norepinephrine.

Recommended protocol

Default to continuous daily use. If you notice the effect is becoming less pronounced, take 5–14 days off and re-evaluate at the original starting dose.

What to monitor on a daily protocol

Common side effects to anticipate with daily use

When to take a planned break

Build deliberate gaps into your use of Atomoxetine (Strattera). Treat daily use as the exception, not the default.

Protocol note from the Atomoxetine (Strattera) entry

Prescription required. Effects build over weeks.

Full mechanism, safety profile, and citations for Atomoxetine (Strattera) are on the main reference page — see Atomoxetine (Strattera). For the dose protocol see Atomoxetine (Strattera) dosage. Use the cycle planner to design a personal cycling schedule.

Daily-use guidance reflects published clinical and observational literature plus consensus practice in the nootropics community. Individual response varies; pregnancy, lactation, and prescription medications change the calculus. Coordinate ongoing protocols with a qualified clinician. See our full disclaimer.